Prostate cancer: abiraterone acetate beats cabazitaxel

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.667, 2012-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Abiraterone Acetate: In Metastatic Castration-Resistant Prostate Cancer

By Yang Lily P.H.

Drugs, Vol. 71, Iss. 15, 2011-10 ,pp. : 2067-2077

Adis International

Access to resources Recommend Favorite

Abiraterone acetate for castration resistant prostate cancer

By Shah Shreya Ryan Charles

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 4, 2010-04 ,pp. : 563-570

Informa Healthcare

Access to resources Recommend Favorite

Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer

By Scott Lesley J. Yang Lily P.H. Lyseng-Williamson Katherine A.

Drugs & Aging, Vol. 29, Iss. 3, 2012-03 ,pp. : 243-248

Adis International

Access to resources Recommend Favorite

Abiraterone acetate for the treatment of prostate cancer

By Ryan Charles J Cheng Michael L

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 1, 2013-01 ,pp. : 91-96

Informa Healthcare

Access to resources Recommend Favorite

Cabazitaxel for the treatment of prostate cancer

By Michielsen Dirk PJ Braeckman Johan G Denis Louis

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 6, 2011-04 ,pp. : 977-982

Informa Healthcare

Access to resources Recommend Favorite